Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plaque rupture, thrombosis, and therapeutic implications

V Fuster1, J Badimon, J H Chesebro

  • 1Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA.

Haemostasis
|October 1, 1996
PubMed
Summary

Atherosclerotic plaque progression, particularly lipid-rich vulnerable plaques, drives acute coronary syndromes (ACS). Lipid-lowering therapies stabilize plaques by promoting cholesterol efflux, reducing ACS risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel role of bone morphogenetic protein-7 in the regulation of adhesion and migration of human monocytic cells.

Thrombosis research·2016
Same author

Identification of fibrillins as a major component of coronary atherosclerotic plaques.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2015
Same author

Muramidase: A useful monocyte/macrophage immunocytochemical marker in swine, of special interest in experimental cardiovascular disease.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2015
Same author

Splice variants of tissue factor promote monocyte-endothelial interactions by triggering the expression of cell adhesion molecules via integrin-mediated signaling.

Journal of thrombosis and haemostasis : JTH·2011
Same author

Hirudin and other thrombin inhibitors experimental results and potential clinical applications.

Trends in cardiovascular medicine·2011
Same author

Bone morphogenetic protein -7 increases thrombogenicity of lipid-rich atherosclerotic plaques via activation of tissue factor.

Thrombosis research·2010

Area of Science:

  • Cardiovascular Medicine
  • Pathology
  • Pharmacology

Background:

  • Atherosclerosis is a complex disease characterized by plaque buildup in arteries.
  • Acute coronary syndromes (ACS) are a major cause of mortality worldwide.
  • Understanding the mechanisms of plaque progression is crucial for developing effective treatments.

Purpose of the Study:

  • To elucidate the basic mechanisms of atherosclerotic lesion progression leading to ACS.
  • To define different types of atherosclerotic lesions and their role in disease.
  • To explore the impact of lipid-modifying strategies and antithrombotic approaches on vulnerable plaques.

Main Methods:

  • Classification of atherosclerotic lesions into eight morphological types (Type I-VI).
  • Investigation of vulnerable lipid-rich plaques and their association with ACS.

Related Experiment Videos

  • Analysis of the role of monocytes/macrophages and the tissue factor pathway in thrombosis.
  • Evaluation of the effects of lipid-modifying strategies on plaque composition and stability.
  • Review of current and evolving antithrombotic strategies.

    • Main Results:

    • Type IV and Va lesions are small but vulnerable, prone to disruption.
    • Macrophage-derived metalloproteinases contribute to plaque instability.
    • Monocytes/macrophages promote thrombin generation via the tissue factor pathway, critical in ACS.
    • Lipid-modifying strategies reduce plaque softness by promoting cholesterol efflux.
    • Risk factor modification favorably influences LDL-cholesterol dynamics in plaques.

    Conclusions:

    • The pathogenesis of ACS involves vulnerable plaque disruption and subsequent thrombosis.
    • Lipid-lowering therapies enhance plaque stability and reduce ACS risk.
    • Targeting the tissue factor pathway and employing antithrombotic strategies are key therapeutic avenues for ACS.